The tenth meeting of the Emergency Committee convened by the WHO Director-General under the International Health Regulations (2005) (IHR) regarding the coronavirus disease (COVID-19) pandemic took place on Thursday 13 January 2022 from 12:00 to 17:00 Geneva time (CEST).
Members and Advisors of the Emergency Committee were convened by videoconference.
The Director-General welcomed the Committee members and advisers. He highlighted the challenges posed by the high transmission levels of the SARS CoV-2 Omicron variant of concern (VOC) and the corresponding burden on public health systems and health service delivery. The Director-General emphasized the importance of vulnerable populations in all countries getting timely and equitable access to COVID-19 vaccination. The Director-General encourages all efforts to expand access to and uptake of vaccination, with the expectation that those who have access to vaccines get vaccinated and continued adherence to PHSM. The DG expressed hope that, by working together, the world can bring an end to the acute phase of the COVID-19 pandemic.
Representatives of the Office of Legal Counsel (LEG) and the Department of Compliance, Risk Management, and Ethics (CRE) briefed the members on their roles and responsibilities. The Ethics Officer from CRE provided the members and advisers with an overview of the WHO Declaration of Interests process. The members and advisers were made aware of their individual responsibility to disclose to WHO, in a timely manner, any interests of a personal, professional, financial, intellectual or commercial nature that may give rise to a perceived or direct conflict of interest. They were additionally reminded of their duty to maintain the confidentiality of the meeting discussions and the work of the Committee. Each member who was present was surveyed. No conflicts of interest were identified.
The Secretariat turned the meeting over to the Chair, Professor Didier Houssin. Professor Houssin noted the continuing challenges caused by SARS-CoV-2 nearly two years after the first meeting of this Committee. He reviewed the objectives and agenda of the meeting.
The Secretariat presented on the current status of the COVID-19 pandemic and a vision for how to optimize the 2022 response to the COVID-19 pandemic. The presentation focused on:
The Committee discussed key issues including:
The Committee praised South Africa for their rapid identification, and transparent and rapid sharing of information on the Omicron VOC. The Committee was concerned about the reaction of States Parties in implementing blanket travel bans, which are not effective in suppressing international spread (as clearly demonstrated by the Omicron experience), and may discourage transparent and rapid reporting of emerging VOC.
The Committee noted with concern reports of violence against health workers, public health officials, and expert advisors engaged in the COVID-19 response. The Committee condemns these acts that undermine national and global response efforts.
The Committee expressed deep concern that countries not eligible for the COVAX Facility Advance Market Commitment (AMC) are experiencing challenges affording COVID-19 vaccines. In addition, they noted challenges posed by the high prices of certain therapeutics, the lack of equity in access, and limited data availability on cost-effectiveness of these treatments. The Committee urged WHO to continue its work with the pharmaceutical sector to address barriers to access and affordability, by expanding tiered pricing, voluntary license agreements and other approaches to increase access to vaccines, therapeutics, and diagnostic tests for all countries, possibly looking at the Pandemic Influenza Preparedness Framework for guidance.
While current vaccines continue to be effective in reducing risk of severe disease and death due to COVID-19, they do not completely eliminate the risk of transmission of SARS-CoV-2 (all variants). A coordinated global strategy is critical for assuring protection of high-risk populations everywhere, with particular focus in countries that have low vaccination rates, especially those with a rate below 10%. To derive the optimal vaccination strategy for reducing infection, morbidity and mortality, the Committee stressed the importance of coordinating research on heterologous vaccine combinations, considering also the natural immunity following infection, and the need for manufacturers to produce and share the relevant data. In addition, the Committee noted the importance of expediting research and development on novel vaccine technologies. The current vaccination technology is dependent on syringes which are in limited supply, presenting a significant logistical and programmatic burden. Rapid development of alternative vaccine formulations, such as intranasal vaccines, could increase the ease of delivery in low resource and/or hard to reach areas. Also, there is a clear need for continued work on vaccines that confer broader immunity across variants. The Committee acknowledged the work of other WHO technical advisory groups such as the Scientific and Technical Advisory Group on Infectious Hazards (STAG-IH), the Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC), the Strategic Advisory Group of Experts on Immunization (SAGE), the Research and Development Blueprint for Epidemics working groups and the Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) that are having on-going in-depth discussions on the key elements of vaccine composition, strategy development, and virus evolution, and are regularly reporting on their findings.
The Committee recognized the challenges in sensitivity and quality posed by the multitude of existing SARS-CoV-2 diagnostic tests in light of the evolving virus, and the lack of appropriate approval for some of their uses, for example testing for access to facilities. This highlighted the need for coherent testing strategies, with clear articulation of what type of tests are to be used for what purposes. The Committee noted the need for regulatory authorities to ensure diagnostic tests meet the WHO standards on specificity and sensitivity for the different applications, including use of assays for testing for access. Continued coordination amongst States Parties is needed to ensure availability and use of high-quality rapid antigen tests in all countries for an effective global response to the pandemic.
The Committee recognized the challenges to maintain continued community buy in for public health and social measures (PHSM) after nearly two years of the COVID-19 pandemic and the risk of overly optimistic statements regarding the state of the pandemic. The Committee further emphasized the need to uphold the ethical and human rights considerations in the application of individualized PHSM, as per WHO guidance.
The Committee unanimously agreed that the COVID-19 pandemic still constitutes an extraordinary event that continues to adversely affect the health of populations around the world, poses a risk of international spread and interference with international traffic, and requires a coordinated international response. As such, the Committee concurred that the COVID-19 pandemic remains a PHEIC and offered its advice to the Director-General.
The Director-General determined that the COVID-19 pandemic continues to constitute a PHEIC. He accepted the advice of the Committee and issued the Committee’s advice to States Parties as Temporary Recommendations under the IHR
The Emergency Committee will be reconvened within three months or earlier, at the discretion of the Director-General. The Director-General thanked the Committee for its work.
Temporary Recommendations to States Parties
The Committee identified the following actions as critical for all countries:
Subscribe to our newsletters →
Related
News
